Full text
Earnings transcript
Read the complete earnings call transcript.
SUPN
Supernus Pharmaceuticals, Inc.
$50.48
-0.96
(-1.87%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 2.907B |
| Shares Outstanding: | 13.855M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – Specialty & Generic | |||||
| CEO: | Jack A. Khattar | |||||
| Full Time Employees: | 674 | |||||
| Address: |
| |||||
| Website: | https://www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson’s disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 607,521 | 661,817 | 718,952 |
| Gross Profit | 523,742 | 583,911 | 644,390 |
| EBITDA | 90,043 | 178,284 | 41,004 |
| Operating Income | -5,269 | 81,666 | -36,864 |
| Net Income | 1,316 | 73,865 | -38,550 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,277,673 | 1,368,073 | 1,452,648,000 |
| Total Liabilities | 356,157 | 332,340 | 390,934,000 |
| Total Stockholders Equity | 921,516 | 1,035,733 | 1,061,714,000 |
| Total Debt | 41,527 | 34,271 | 30,365,000 |
| Cash and Cash Equivalents | 75,054 | 69,331 | 128,448,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 111,085 | 171,951 | 47,331 |
| Capital Expenditure | -551 | -725 | -1,338 |
| Free Cash Flow | 110,534 | 171,226 | 45,993 |
| Net Income | 1,316 | 73,865 | -38,550 |
| Net Change in Cash | -18,066 | -5,723 | 60,567 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,346,625.063 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,391,844.841 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,369,283.250 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 249,745.755 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 258,132.238 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 253,947.954 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 387,209.638 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 404,198.608 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 395,722.470 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 761,489.246 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 787,060.116 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 774,301.992 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 7.010 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 7.160 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 6.860 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates SUPN intrinsic value between $44.20 – $45.02 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about SUPN valuation
Is Supernus Pharmaceuticals, Inc. (SUPN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Supernus Pharmaceuticals, Inc. (SUPN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SUPN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SUPN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SUPN’s P/E ratio?
You can see SUPN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SUPN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SUPN a good long-term investment?
Whether SUPN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SUPN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-1.87
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 29.16 | Year High: | 59.68 | |
| Price Avg 50: | 51.05 | Price Avg 200: | 45.92 | |
| Volume: | 457885 | Average Volume: | 691539 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
